Cargando…
Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH) and associated end-stage liver disease is a growing cause of concern throughout the Western world. It constitutes a significant clinical burden for which therapeutic approaches are very limited. Over the last years, considerable attention has therefore been paid...
Autores principales: | De Ponti, Federico F., Scott, Charlotte L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366860/ https://www.ncbi.nlm.nih.gov/pubmed/35913023 http://dx.doi.org/10.1042/CS20220258 |
Ejemplares similares
-
FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
por: Liu, Cong, et al.
Publicado: (2023) -
Targeting the Annexin A1-FPR2/ALX pathway for host-directed therapy in dengue disease
por: Costa, Vivian Vasconcelos, et al.
Publicado: (2022) -
Role of macrophage scavenger receptor MSR1 in the progression of non-alcoholic steatohepatitis
por: Sheng, Wei, et al.
Publicado: (2022) -
Macrophages regulate gastrointestinal motility through complement component 1q
por: Pendse, Mihir, et al.
Publicado: (2023) -
M1/M2 macrophages and their overlaps – myth or reality?
por: Strizova, Zuzana, et al.
Publicado: (2023)